VYNE Therapeutics
VYNE
33 hedge funds and large institutions have $18.4M invested in VYNE Therapeutics in 2023 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 1 closing their positions.
1,200% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 1
1,095% more capital invested
Capital invested by funds: $1.54M → $18.4M (+$16.9M)
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
57% more funds holding
Funds holding: 21 → 33 (+12)
44.91% more ownership
Funds ownership: 11.69% → 56.61% (+45%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$4.35M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$4.35M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$3.68M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$2.19M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$2.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$48.1K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2.9K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.99K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$513 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MLA
26
MB, Levis & Associates
Center Valley,
Pennsylvania
| $2.43K | – | – | – |
|
27
UBS Group
Zurich,
Switzerland
| $1.97K | +$2.06K | +662 | +360% |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| $1.84K | +$1.62K | +521 | +194% |
|
29
Russell Investments Group
London,
United Kingdom
| $435 | – | – | – |
|
30
Wells Fargo
San Francisco,
California
| $400 | +$209 | +67 | +64% |
|
31
JP Morgan Chase
New York
| $341 | – | – | – |
|
|
SPIA
32
Steward Partners Investment Advisory
New York
| $51 | – | – | – |
|
|
ITIM
33
Indiana Trust & Investment Management
Mishawaka,
Indiana
| $28 | – | – | – |
|
|
34
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$513 | -127 | Closed |
|
VYNE Hedge Fund Activity: Q4 2023 in Review
33 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q4 2023, worth a combined $18.4M — up 1,095% from $1.54M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new VYNE positions and 1 closed out — a net gain of 12 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $4.35M. The largest seller was Susquehanna International Group, cutting an estimated $48.1K.
- 33 institutional investors held VYNE Therapeutics (VYNE) as of Q4 2023, up from 21 in Q3 2023.
- Funds reported $18.4M of VYNE Therapeutics stock for Q4 2023, up 1,095% quarter-over-quarter.
- 13 funds opened new VYNE Therapeutics positions in Q4 2023 and 1 closed out, a net change of +12 holders.
- The largest VYNE Therapeutics buyer in Q4 2023 was Cormorant Asset Management, an estimated $4.35M added.
- The largest VYNE Therapeutics seller in Q4 2023 was Susquehanna International Group, an estimated $48.1K sold.
Based on aggregated 13F filings for Q4 2023.